Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73.41 USD | +1.96% | +12.46% | +3.45% |
Apr. 18 | Intra-Cellular Therapies Prices $500 Million Stock Offering | MT |
Apr. 17 | Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating | MT |
Financials (USD)
Sales 2024 * | 659M | Sales 2025 * | 920M | Capitalization | 7.51B |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | 104M | EV / Sales 2024 * | 10.6 x |
Net cash position 2024 * | 532M | Net cash position 2025 * | 633M | EV / Sales 2025 * | 7.47 x |
P/E ratio 2024 * |
-107
x | P/E ratio 2025 * |
61.4
x | Employees | 610 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.4% |
Latest transcript on Intra-Cellular Therapies, Inc.
1 day | -6.12% | ||
1 week | +5.93% | ||
Current month | +4.05% | ||
1 month | +10.14% | ||
3 months | +10.53% | ||
6 months | +37.96% | ||
Current year | +0.53% |
Managers | Title | Age | Since |
---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 13-08-28 |
Director of Finance/CFO | 67 | 13-08-28 | |
Michael Halstead
PSD | President | 51 | 14-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 14-01-07 |
Joel Marcus
BRD | Director/Board Member | 76 | 13-08-28 |
Director/Board Member | 67 | 14-01-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.14% | 16 M€ | -9.75% | ||
0.45% | 0 M€ | 0.00% | - | |
0.40% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 74.12 | +2.94% | 218 147 |
24-04-18 | 72 | -6.12% | 4,711,039 |
24-04-17 | 76.69 | -3.95% | 2,862,199 |
24-04-16 | 79.84 | +23.29% | 7,381,356 |
24-04-15 | 64.76 | -1.70% | 503,322 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.53% | 7.51B | |
-5.99% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+52.79% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-15.88% | 11.86B | |
-10.45% | 11.79B | |
-2.70% | 8.07B |
- Stock Market
- Equities
- ITCI Stock